correction to orbec data
On intention-to-treat analysis, oral BDP was associated with 37% and 45% reductions in the risk of GVHD-treatment failure at study day 50 and at 30 days follow-up, respectively. The corresponding risk reductions among patients eligible for the prednisone taper at day 10 were 61% and 62%.
By day 200 after transplantation, 5 BDP-treated patients had died compared with 16 control patients, a risk reduction of 67% (p = 0.03). The reduction in mortality risk with BDP was even more pronounced among subjects who had received unrelated and HLA-mismatched stem cells -- 91% (p = 0.02). The survival benefit was still apparent 1 year after randomization.
The P value at 200 day survival is .013, not .03
As I said the data is not supericially similar, Provenge data doesn't come close
